Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on KALIBRATE TECHNOLOGIES PLC. We currently have 16 research reports from 1 professional analysts.
|22Feb17 09:38||RNS||Holding(s) in Company|
|16Feb17 09:00||RNS||Notice of Results|
|31Jan17 09:19||RNS||Holding(s) in Company|
|27Jan17 15:17||RNS||Holding(s) in Company|
|24Jan17 07:00||RNS||Trading Update|
|12Jan17 13:25||RNS||Holding(s) in Company|
|30Dec16 09:00||RNS||Total Voting Rights|
Frequency of research reports
Research reports on
KALIBRATE TECHNOLOGIES PLC
KALIBRATE TECHNOLOGIES PLC
N+1 Singer - Kalibrate Technologies - Trading update – contract delays
24 Jan 17
Kalibrate issued a trading update indicating revenue and EBITDA for the current financial year (ending June 2017) are expected to be materially below expectations. Delays to signing of contracts and the commencement of certain backlog projects are the key reasons. The group had indicated last Sept that its continued growth is predicated on securing significant wins in Rest of World (India, Asia and Latin America), the timing of which is difficult to predict. The group has already taken action to reduce the cost base to protect profitability and cash (net cash stood at $3.1m, up from $2.4m in FY’16). We have put our forecasts under review, but expect the group to be profitable in the current year. Kalibrate has a strong market position and has significant opportunities for cross-selling within its customer base. So whilst there are near-term revenue challenges, we believe the group’s medium-term prospects, particularly with its continued investments in Rest of World, Merchandising and B2B Pricing, remain healthy.
N+1 Singer - Morning Song 24-01-2017
24 Jan 17
Harwood Wealth (HW LN) FY16 EBITDA 11% ahead, positive strategic progress | Horizon Discovery Group (HZD LN) Positive trading update, 2017e EBITDA guidance maintained | Kalibrate Technologies (KLBT LN) Trading update – contract delays | Marston’s (MARS LN) Decent start to the year | Murgitroyd Group (MUR LN) H1 trading behind budget | NCC Group (NCC LN) Rebuilding credibility from a sound base | Restore (RST LN) Positive conclusion to FY16 confirmed | Servelec Group (SERV LN) In line FY16 trading update | Xaar (XAR LN) Announcement of new FD
N+1 Singer - Morning Song 20-09-2016
20 Sep 16
Augean (AUG LN) Good H1 performance | Cello Group (CLL LN) Still moving in the right direction | Genus (GNS LN) Gene edited animals: exciting, but increases risk | Horizon Discovery Group (HZD LN) Interims and FY2016 guidance in line with expectations | Kalibrate Technologies (KLBT LN) In-line results; investing for growth | PuriCore (PURI LN) Disposal of Supermarket Retail | Swallowfield (SWL LN) Strong delivery in core business and owned brands
N+1 Singer - Kalibrate Technologies - In-line results; investing for growth
20 Sep 16
Kalibrate’s FY’16 revenues were slightly shy of our expectations but adjusted EBITDA was in line. SaaS transition continues, with annualised recurring revenues up 10%, but perpetual deals remain a feature (2 large deals in late Q4). The shape of the pipeline suggests there are some sizeable contracts to close, but the group is encouraged by developments and we make no changes to P&L forecasts. Given its track record and leadership in developed markets, Kalibrate is well-positioned in new markets that are deregulating. In addition, a broadening product set offers substantial cross-selling opportunities. Its medium-term prospects and competitive position remain strong.
FY outlook unchanged by H1 timing delays
15 Mar 16
Kalibrate delivered strong progress against its key metrics around core markets and new geographies, cross-selling, driving SaaS and recurring revenues and expanding product capability. However, the group’s interim performance was impacted by 3 pricing deals that slipped into H2, all of which have now been signed. Its FY outlook is unchanged, as are our forecasts, supported by a healthy pipeline. With more activity in the countries that have recently deregulated, more markets deregulating and a broader offering with Merchandising, we remain enthused as to its prospects and believe it is well positioned to capitalise on the growth opportunity.
05 Feb 16
Grainger (GRI LN) Disposal of German portfolio to Heitman for £94m | Halma (HLMA LN) Acquisition of CenTrak | Kalibrate Technologies (KLBT LN) Capital Markets Day: Resounding endorsement from a customer at time of significant opportunity | Retail | Victrex (VCT LN) Value in Motor Retail, encouraging stats in car markets
N+1 Singer - NCC Group - Further issues in Assurance
22 Feb 17
NCC released a trading update yesterday afternoon highlighting further issues in its Assurance division. Sales growth has been lower than expected in all regions, resulting in a significant reduction in full year expectations. We have reduced our EPS forecasts by 25% in FY’17 and 22%/25% in FY’18/’19 respectively. Escrow continues to perform in line with expectations. In response to these issues the Board has announced a strategic review into all of the Assurance businesses. The results of the strategic review are expected to be announced at the FY results in July. With an extended period of uncertainty on the horizon we believe it will be hard for investors to gain confidence in NCC in the short term. That said we see fundamental value in the stock. Escrow is unaffected by this warning and remains an extremely high quality business, which we value at £353m in our SOTP. At the current share price this leaves Assurance valued at c.5x cal’17 EBITDA. While this appears to be an attractive multiple for a rare cybersecurity asset, we would like further clarity on the underlying nature of the current issues, hence our Hold recommendation. Our 138p target price assumes a 12x EBITDA multiple for Assurance but we apply a 20% discount to the group to account for the current uncertainty.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
N+1 Singer - PROACTIS Holdings - H1 in line
20 Feb 17
A positive interim trading update confirms that H1 results are in line with expectations, with revenues up 36% to c£11.8m on the back of strong organic growth (13%) and an in-line contribution from acquisitions. We make no changes to our forecasts, recommendation and target price pending the release of interim results on 26 April.